
STARGLO: Glofitamab Plus Chemo Meets Primary OS End Point in R/R DLBCL in Phase 3 Study
Results show the bispecific antibody is effective in an earlier line of treatment.
The phase 3 STARGLO study, which is evaluating glofitamab plus chemotherapy in patients with relapsed or refractory (R/R)
The study (
Adverse events (AEs) were consistent with the known safety profiles of the combination, the statement said. The most common AE is cytokine release syndrome.
Glofitamab, sold as Columvi, is a fixed-duration, bispecific CD20-directed CD3 T-cell engager that received
Approvals from FDA and the European Commission were based on results from a pivotal, single-arm phase 1/2 study of the drug as monotherapy (NCT03075696) in patients with R/R DLBCL who had received at least 2 prior treatments.
In Sunday’s statement, Genentech said these new data will be shared with regulators and presented at an upcoming scientific meeting.
“People with this aggressive lymphoma facing relapse or progression after initial treatment have limited options – particularly those who are ineligible for stem cell transplant,” said Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of Global Product Development. “Building on [glofitamab’s] established benefits, these data demonstrate the potential of this combination regimen to improve survival outcomes in earlier lines of treatment.”
Reference
Genentech’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in phase III STARGLO study. News release. Genentech. April 14, 2024. Accessed April 15, 2024. https://www.businesswire.com/news/home/20240414728020/en/Genentech%E2%80%99s-Columvi-Meets-Primary-Endpoint-of-Overall-Survival-in-People-With-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma-in-Phase-III-STARGLO-Study
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.